首页> 外文OA文献 >Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years : 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

【2h】

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years : 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

机译：25岁以上女性使用人乳头瘤病毒16/18 AS04辅助疫苗的功效，安全性和免疫原性：3期，双盲，随机对照VIVIANE研究的7年随访

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Acknowledgments The VIVIANE study was funded and coordinated by GlaxoSmithKline Biologicals SA, which also covered all costs associated with development and publication of this report. We thank all study participants and their families. We gratefully acknowledge the work of the central and local study coordinators, and staff members of the sites who participated in this study. Writing support services were provided by Mary Greenacre (An Sgriobhadair, Isle of Barra, UK), on behalf of GSK Vaccines; editing and publication coordination services were provided by Jérôme Leemans (Keyrus Biopharma, Lasne, Belgium), Stéphanie Delval (XPE Pharma and Science, Wavre, Belgium), and Matthieu Depuydt (Business Decision Life Sciences, Brussels, Belgium), on behalf of GSK Vaccines

机译：致谢VIVIANE研究由葛兰素史克（GlaxoSmithKline Biologicals SA）资助和协调，该研究还涵盖了与开发和发布本报告相关的所有费用。我们感谢所有的研究参与者及其家人。我们衷心感谢中央和地方研究协调员以及参与本研究的站点工作人员的工作。玛丽·格林纳克雷（Mary Greenacre）（英国，巴拉岛的安哥里达哥都航空）代表GSK疫苗提供了写作支持服务； JérômeLeemans（比利时Lasne的Keyrus Biopharma），StéphanieDelval（比利时Wavre的XPE Pharma and Science）和Matthieu Depuydt（比利时布鲁塞尔的商业决策生命科学）提供了编辑和出版协调服务。疫苗

著录项

作者
Wheeler, Cosette M; Skinner, S Rachel; Del Rosario-Raymundo, M Rowena; Garland, Suzanne M; Chatterjee, Archana; Lazcano-Ponce, Eduardo; Salmerón, Jorge; McNeil, Shelly; Stapleton, Jack T; Bouchard, Céline; Martens, Mark G; Money, Deborah M; Quek, Swee Chong; Romanowski, Barbara; Vallejos, Carlos S; Harmsel, Bram ter; Prilepskaya, Vera; Fong, Kah Leng; Kitchener, Henry; Minkina, Galina; Lim, Yong Kuei Timothy; Stoney, Tanya; Chakhtoura, Nahida; Cruickshank, Margaret E; Savicheva, Alevtina; da Silva, Daniel Pereira; Ferguson, Murdo; Molijn, Anco C; Quint, Wim GV; Hardt, Karin; Descamps, Dominique; Suryakiran, Pemmaraju; Karkada, Naveen; Geeraerts, Brecht; Dubin, Gary; Struyf, Frank;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献

1. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study [J] . Wheeler Cosette M., Skinner S. Rachel, Rowena Del Rosario-Raymundo M., The Lancet infectious diseases . 2016,第10期

机译：25岁以上女性使用人乳头瘤病毒16/18 AS04辅助疫苗的疗效，安全性和免疫原性：3期，双盲，随机对照VIVIANE研究的7年随访
2. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study [J] . Skinner S. Rachel, Szarewski Anne, Romanowski Barbara, The Lancet . 2015,第9961期

机译：人乳头瘤病毒的疗效，安全和免疫原性16/18女性乳头毒性疫苗疫苗，女性妇女在25岁以上：4年临时后续3阶段，双盲，随机控制的Viviane研究
3. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: Follow-up through Month 48 in a Phase III randomized study [J] . Einstein Mark H., Levin Myron J., Chatterjee Archana, Human vaccines & immunotherapeutics. . 2014,第12期

机译：18-45岁健康女性中人乳头瘤病毒（HPV）-16/18 AS04辅助疫苗和HPV-6 / 11/16/18疫苗的体液和细胞免疫原性和安全性比较：随访至第48个月III随机研究
4. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study [O] . Mark H Einstein, Myron J Levin, Archana Chatterjee, 2014

机译：18-45岁健康女性中人乳头瘤病毒（HPV）-16/18 AS04辅助疫苗和HPV-6 / 11/16/18疫苗的体液和细胞免疫原性和安全性比较：随访至第48个月III随机研究
5. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: Follow-up from months 12–24 in a Phase III randomized study of healthy women aged 18–45 years [O] . Einstein, Mark H, Baron, Mira, Levin, Myron J, 2011

机译：人乳头瘤病毒（HPV）-16/18疫苗和HPV-6 / 11/16/18疫苗的免疫原性和安全性比较：一项针对年龄在18-45岁之间的健康女性的III期随机研究中的12-24个月随访

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years : 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

摘要

著录项

相似文献

相关主题

期刊订阅